Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > JMT101 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF COLORECTAL CANCER

JMT101 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF COLORECTAL CANCER

June 02, 2025

a250602a_00.png

Previous: VOLUNTARY ANNOUNCEMENT - COBAMAMIDE CAPSULES OBTAIN DRUG REGISTRATION APPROVAL

Next: JMT106 (BISPECIFIC FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat